Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024
A Supportive Membership Offer While You Plan Your Next Step
Being made redundant, or finding yourself between roles for any reason, can be an unsettling time. It can also be an important moment to reconnect with your professional community, explore new opportunities, and invest in your next step.
About Spliceor
Spliceor is a University of Cambridge spin-out, backed by venture funding.
We are building next-generation programmable RNA technology to treat cancer and inflammatory conditions in new ways.
Stevenage, UK, 21 October 2026 - NRG Therapeutics Ltd. (“NRG”), an innovative clinical stage neuroscience company targeting a novel mechanism to restore mitochondrial dysfunction in neurodegenerative diseases, today announced a positron emission tomography (PET) imaging trial (NRG5051-102) to assess the biodistribution of its lead clinical asset NRG5051 has started.
NRG5051 is an orally bioavailable and CNS-penetrant next-generation inhibitor of the mitochondrial permeability transition pore (mPTP) that acts through a novel NLRX1-mediated mechanism of action.
Do you want to use your engineering skills to build agentic workflows that help find treatments for rare disease patients?
About Healx
15 Oct 2026
Graham Hewson has been appointed as Chief Business Officer of the Royal Veterinary College (RVC) and Chief Executive Officer of the London Bioscience Innovation Centre (LBIC).
About us
Cancer Research UK (CRUK) is the world's largest independent funder of oncology research, with an annual R&D spend of over £400 million, and a network of over 4,000 researchers at 90 institutions across the UK and beyond.
Sandwich, UK — 13 October 2026: Discovery Park, Kent’s business park for science and technology companies, today welcomed two climate-tech companies to its innovation campus. Anthera Remediation Technologies, tackling 'forever chemicals' in water and soil, and Colliding Materials, building plastic compounding technology for sustainable energy systems, have now moved into new laboratory spaces in Sandwich, Kent.
Join scientists from leading pharmaceutical, biotechnology and academic organizations as they share how they are applying Organ-on-a-Chip (OOC) human-relevant models to improve decision-making across research and development.
The program includes a dedicated OOC Masterclass, designed to help attendees understand the technology, explore practical applications and learn how others are successfully implementing these approaches.